Allergan Teams Up with a Host of Celebrities to Encourage Alzheimer's Patients and their Caregivers to Hold on to Hope

DUBLIN, June 5, 2018 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that, in honor of Alzheimer's & Brain Awareness Month, it is teaming up with notable celebrities Scott Conant, Sean Hayes, Helen Hunt, Soleil Moon Frye, Molly Sims and Trista Sutter to shine light on what can be a very challenging time for Alzheimer's caregivers, as part of the company's 'Hold on to Hope' initiative.

'Hold on to Hope' was created to give caregivers hope in a space where they often feel defeated, and features both an educational website ( and a powerful video that uses lightbulbs as a metaphor for the disease. Since its launch in December 2017, the 'Hold on to Hope' initiative has seen nationwide attention via various digital platforms and television spots designed to spark a conversation around the efforts of Alzheimer's caregivers who care so deeply for their loved ones.

To drive the conversation further, Allergan is partnering with a network of celebrities, many of whom have been closely affected by the disease, to extend the reach of the campaign for Alzheimer's & Brain Awareness Month. Throughout the month of June, these partners will take to Instagram and Facebook to encourage people to 'Hold on to Hope' while honoring caregivers for their ongoing, and unwavering, efforts.

"I am proud to align myself with Allergan to bring much needed awareness and recognition for the challenges Alzheimer's caregivers face," said Scott Conant, Celebrity Chef. "I deeply admire the commitment these people have for their loved ones affected by the disease, and want to do my part in spreading awareness and respect."

Allergan's overall goal for this campaign is to help caregivers hold on to hope despite the challenges Alzheimer's poses-- whether that be helping caregivers connect to others in a similar situation, offering education about the stages of the disease to better deal with the developing symptoms, or helping them learn about available treatments.

"Allergan is committed to offering support to those who suffer from Alzheimer's Disease, whether that be through education about the disease, resources and networks for caregivers, or treatment options for patients," said Will Kane, Senior Vice President, U.S. General Medicine, Allergan. "Through this platform, we hope to create a sense of community for caregivers specifically, and are delighted to have the help of several influential names to generate awareness for this initiative."

To learn more about the stages of Alzheimer's Disease and to find resources for caregivers, visit

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended March 31, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.


Daphne Karydas
(862) 261-8006

Karina Calzadilla
(862) 261-7328

Amy Rose
(862) 289-3072

Frances DeSena
(862) 261-8820

View original content with multimedia:

SOURCE Allergan plc


Back to news